Sickle Cell Disease Clinical Trial Pipeline Highlights 2019 - Global Forecast to 2024 by Clinical Trial Stages, Drug Mechanism Classes, Company - ResearchAndMarkets.com

DUBLIN--()--The "Global Sickle Cell Disease Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Sickle Cell Disease Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Sickle Cell Disease market. It covers emerging therapies for Sickle Cell Disease in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives in tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Sickle Cell Disease pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Sickle Cell Disease pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Sickle Cell Disease pipeline products by the company.

Short-term Launch Highlights:

Find out which Sickle Cell Disease pipeline products will be launched in the US and Ex-US to 2024.

Key Topics Covered:

1. Sickle Cell Disease Pipeline by Stages

2. Sickle Cell Disease Phase 3 Clinical Trial Insights

3. Sickle Cell Disease Phase 2 Clinical Trial Insights

4. Sickle Cell Disease Phase 1 Clinical Trial Insights

5. Sickle Cell Disease Preclinical Research Insights

6. Sickle Cell Disease Discovery Stage Insights

7. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ysssbc

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Hematological Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Hematological Drugs